Hepatitis After Intravenous Injection of Sublingual Buprenorphine in Acute Hepatitis C Carriers: Report of Two Cases of Disappearance of Viral Replication After Acute Hepatitis

Abstract

Spanish

French

Objective

To report 2 cases of acute hepatitis related to intravenous administration of buprenorphine in hepatitis C–infected patients.

Case Summary

Two patients, aged 33 and 50 years, respectively, who were hepatitis C virus (HCV) carriers were treated with sublingual buprenorphine 8 mg/day for addiction. Several years after initiation of buprenorphine, they were hospitalized because of clinical hepatitis with jaundice that developed after intravenous injection of buprenorphine. Serum alanine aminotransferase rose to 100 times the upper limit of normal (ULN) in the first patient and to 21 times the ULN in the second. As cofactors, the first patient had consumed alcohol, and the second patient took aspirin 600 mg in addition to the injection of buprenorphine 20 mg 4 days before the onset of jaundice. After stopping the intravenous injections, both patients continued sublingual buprenorphine therapy, with no relapse of hepatitis. Interestingly, in these 2 patients, buprenorphine-induced hepatitis was followed by the disappearance of HCV RNA.

Discussion

Most cases of hepatotoxicity related to buprenorphine have occurred in hepatitis C–infected patients. The main mechanism for buprenorphine-induced hepatitis is a mitochondrial defect, exacerbated by cofactors with additional potential to induce mitochondria dysfunction (eg, HCV, alcohol, concomitant medications). According to the Naranjo probability scale, buprenorphine was found to be the probable cause of acute hepatitis in both patients. In addition, we assessed the relationship between intravenous buprenorphine and acute hepatitis using 2 scales for causality assessment of hepatotoxicity (the Council for International Organizations of Medical Sciences scale and the Maria & Victorino scale). The diagnosis of intravenous buprenorphine-induced hepatitis was classified as probable in both cases. In addition, these 2 cases illustrate that acute hepatitis in a carrier of chronic HCV may occasionally facilitate the clearance of virus.

Conclusions

Although buprenorphine is well tolerated when used at recommended sublingual doses, patients should be informed about the risk of acute hepatitis with misuse of the drug by the intravenous route. These cases illustrate that, in carriers of chronic HCV, acute hepatitis may modify the host's immunotolerance and facilitate clearance of the virus.

Keywords

acute hepatitis buprenorphine hepatitis C injection misuse

Get full access to this article

View all access options for this article.

References

Heel

Brogden

Speight

Avery

. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs 1979;17:81–110.

Product information. Buprenorphine (Subutex) sublingual oral tablets. Richmond, VA: Reckitt Benckiser Pharmaceuticals, Inc., June 2005.

Berson

Gervais

Cazals

. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001;34:346–50.

Houdret

Asnar

Szostak-Talbodec

. Hepatonephritis and massive ingestion of buprenorphine. Acta Clin Belg 1999;1(suppl 1): 29–31.

Herve

Riachi

Noblet

. Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol 2004;16:1033–7.

Zuin

Giorgini

Selmi

. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Dig Liver Dis 2008 Feb 20 [Epub ahead of print].

Naranjo

Busto

Sellers

. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–45.

Danan

Bénichou

. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323–30.

Lucena

Camargo

Andrade

Pérez-Sanchez

Sánchez de la Cuesta

. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001;33:123–30.

10.

Vidal-Trecan

Varescon

Nabet

Boissonnas

. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003;69:175–81.

11.

Roux

Villes

Blanche

. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend 2008;97:105–13.

12.

Berson

Fau

Fornacciari

. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 2001;34:261–9.

13.

Brewster

Humphrey

Mcleavy

. The systemic bioavailability of buprenorphine by various routes of administration. J Pharm Pharmacol 1981;33:500–6.

14.

Walsh

Preston

Stitzer

Cone

Bigelow

. Clincal pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569–80.

15.

Piccoli

Scrima

D'aprile

. Mitochondrial dysfunction in hepatitis C virus infection. Biochim Biophys Acta 2006;1757:1429–37.

16.

Mansouri

Gaou

De Kerguenec

. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology 1999;117:181–90.

17.

Deschamps

Fisch

Fromenty

Berson

Degott

Pessayre

. Inhibition by salicylic acid of the activation and thus oxidation of long chain fatty acids. Possible role in the development of Reye's syndrome. J Pharmacol Exp Ther 1991;259:894–904.

18.

Alberti

Benvegnu

. Management of hepatitis C. J Hepatol 2003;38(suppl 1):S104–18.

19.

Scott

McMahon

Bruden

. High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska natives. Clin Infect Dis 2006;42:945–52

20.

Byrnes

Chopra

Koziel

. Resolution of chronic hepatitis C following parasitosis. World J Gastroenterol 2007;13:4268–9.

21.

Gruener

Jung

Ulsenheimer

. Hepatitis C virus eradication associated with hepatitis B virus superinfection and development of a hepatitis B virus specific T cell response. J Hepatol 2002;37:866–89.

22.

Somsouk

Lauer

Casson

. Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression. Gastroenterology 2003;124:1946–9.

23.

Koziel

. Cellular immune responses against hepatitis C virus. Clin Infect Dis 2005;41(suppl 1):S25–31.

24.

Brunelle

Ledru

Rotily

. Spontaneous clearance of hepatitis C virus after long-term opiate dependence therapy with buprenorphine. J Viral Hepat 2004;11:571–3.

25.

Zhang

Douglas

. Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol 2003;163:1167–75.

26.

Yokosuka

Kojima

Imazeki

. Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases: analysis of HCV RNA in 320 patients who were followed for more than 3 years. J Hepatol 1999;31:394–9.